Cremolini C, et al. - In this phase 2 study, researchers compared metronomic chemotherapy (metroCT) in combination with bevacizumab vs bevacizumab monotherapy as maintenance after 4 months of induction with FOLFOXIRI plus bevacizumab for metastatic colorectal cancer (mCRC). The study sample consisted of patients with unresectable mCRC who were randomized to receive up to eight cycles of FOLFOXIRI plus bevacizumab, followed by bevacizumab (arm A), or the same regimen followed by bevacizumab plus metroCT (capecitabine 500 mg three times daily and cyclophosphamide 50 mg/die; arm B) until disease progression. Between May 2012 and March 2015, a total of 232 patients were randomized in 16 Italian centers, mostly with RAS (65%) or BRAF (9%) mutant tumors. Overall, the addition of metroCT to bevacizumab maintenance did not offer significant progression-free survival benefit in mCRC patients.